Spondyloarthritis & psoriatic arthritis
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
Authors' conclusion
In patients with active PsA who were csDMARD-IR, continuous risankizumab treatment demonstrated robust long-term efficacy and was well tolerated through 52 weeks of treatment.
Study context
- Population
- Patients with active PsA and previous inadequate response/intolerance to ≥1 csDMARD (csDMARD-IR)
- Participants
- 483 vs 481
- Comparison
- Risankizumab 150 mg SC vs placebo at weeks 0, 4 and 16; then open-label risankizumab 150 mg every 12 weeks from week 24 through week 208
- Risankizumabn = 483
- Placebon = 481reference
Methodological detailsphase 3, global, double-blind, placebo-controlled (24-week period 1), open-label extension (period 2), ongoing
- Phase 3
- Global
- Double-blind
- Placebo-controlled (24-week period 1)
- Open-label extension (period 2)
- Ongoing
Primary result
As reported in the abstract
ACR20 · week 24
P < 0.001
Further findings
ACR20 · week 52
- ACR criteria (ACR20): Placebo patients received risankizumab from week 24
Other efficacy measures
- Similar result trends were observed
Original publication
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). Published 25 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →